Financiere des Professionnels Fonds d investissement inc. Sells 123,924 Shares of Becton, Dickinson and Company $BDX

Financiere des Professionnels Fonds d investissement inc. trimmed its position in Becton, Dickinson and Company (NYSE:BDX) by 99.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,100 shares of the medical instruments supplier’s stock after selling 123,924 shares during the quarter. Financiere des Professionnels Fonds d investissement inc.’s holdings in Becton, Dickinson and Company were worth $173,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC boosted its stake in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new stake in Becton, Dickinson and Company during the third quarter worth $7,401,000. Pacific Capital Partners Ltd boosted its position in Becton, Dickinson and Company by 28.2% during the 4th quarter. Pacific Capital Partners Ltd now owns 37,500 shares of the medical instruments supplier’s stock valued at $7,278,000 after acquiring an additional 8,250 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Becton, Dickinson and Company by 4.4% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,900 shares of the medical instruments supplier’s stock valued at $122,403,000 after acquiring an additional 26,671 shares in the last quarter. Finally, Cooke & Bieler LP increased its holdings in shares of Becton, Dickinson and Company by 27.2% in the 4th quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier’s stock valued at $218,614,000 after acquiring an additional 240,673 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 1.1%

Becton, Dickinson and Company stock opened at $158.14 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. The stock has a market cap of $43.57 billion, a PE ratio of 40.04, a price-to-earnings-growth ratio of 11.19 and a beta of 0.21. The stock has a 50-day moving average of $148.99 and a two-hundred day moving average of $166.39. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same quarter in the previous year, the firm earned $3.35 earnings per share. The company’s revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 12.62 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th were given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is currently 106.33%.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of analyst reports. Stifel Nicolaus decreased their price objective on Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Weiss Ratings lowered Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Wells Fargo & Company boosted their target price on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Bank of America decreased their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Finally, Barclays lifted their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $180.29.

Insider Buying and Selling

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,188 shares of company stock worth $765,120 in the last 90 days. 0.40% of the stock is currently owned by company insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.